Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cutaneous vasculitis from maprotiline.

A M Oakley, L Hodge

    Australian and New Zealand Journal of Medicine
    |April 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Maprotiline, a medication for depression, may cause vasculitis, a rare skin condition. This case report highlights a potential adverse drug reaction that resolved after discontinuing the medication.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Successful melanoma triage by a virtual lesion clinic (teledermatoscopy).

    Journal of the European Academy of Dermatology and Venereology : JEADV·2015
    Same author

    Mobile teledermatology is here to stay.

    The British journal of dermatology·2015
    Same author

    Serological evidence of increased Coccidioides immitis infections in western Canada in 1996.

    The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses·2012
    Same author

    Prevalence of zoonotic agents in dogs visiting hospitalized people in Ontario: implications for infection control.

    The Journal of hospital infection·2006
    Same author

    Adverse effects of isotretinoin therapy for acne vulgaris.

    The New Zealand medical journal·2001
    Same author

    Teledermatology in New Zealand.

    Journal of cutaneous medicine and surgery·2001
    Same journal

    Gastroenterological Society of Australia, Annual Scientific Meeting, May 1980.

    Australian and New Zealand journal of medicine·2020
    Same journal

    'A touch of sugar'--a dangerous euphemism still alive and well.

    Australian and New Zealand journal of medicine·2001
    Same journal

    Silent myocardial ischaemia following methysergide overdose.

    Australian and New Zealand journal of medicine·2001
    Same journal

    Extensive jugular and upper limb thrombosis in a patient with factor V Leiden mutation and non-Hodgkin's lymphoma.

    Australian and New Zealand journal of medicine·2001
    Same journal

    Visual loss as the presenting feature of giant cell arteritis.

    Australian and New Zealand journal of medicine·2001
    Same journal

    Lymphoproliferative disease causing angioedema--an uncommon association.

    Australian and New Zealand journal of medicine·2001
    See all related articles

    Area of Science:

    • Dermatology
    • Pharmacology
    • Psychiatry

    Background:

    • Depression is a common mood disorder often treated with antidepressant medications.
    • Maprotiline is a tetracyclic antidepressant used in the management of depression.
    • Adverse drug reactions can manifest in various ways, including dermatological symptoms.

    Observation:

    • An 83-year-old female patient with a diagnosis of depression was undergoing treatment with maprotiline.
    • The patient developed a distinct skin eruption characterized by vasculitis.
    • The vasculitic eruption showed complete resolution upon cessation of maprotiline therapy.

    Findings:

    • This case represents the first reported instance of vasculitis associated with maprotiline use.
    • The temporal relationship between maprotiline administration and the onset of vasculitis suggests a potential drug-induced etiology.

    Related Experiment Videos

  • Discontinuation of maprotiline led to the resolution of the skin condition, supporting the causal link.
  • Implications:

    • Clinicians should be aware of the potential for maprotiline to induce vasculitis, a previously unreported adverse effect.
    • Early recognition and discontinuation of the offending drug are crucial for managing drug-induced vasculitis.
    • Further investigation may be warranted to elucidate the mechanism underlying maprotiline-induced vasculitis.